Profiling of LPS-Induced Acute Systemic Inflammation in the Mouse

Inflammation has recently become implicated in the development and progression of disease in many areas such as oncology, metabolic disorders as well as neurodegeneration. Inflammatory diseases have a high socioeconomic burden producing significant morbidity, (pain, impaired function, diminished quality of life) as well as economic impacts (absenteeism, decreased productivity, healthcare costs), plus mortality across the globe.

In this poster we demonstrate the reproducibility of our Lipopolysachharide (LPS) mouse model, both in terms of the initial cytokine response as well as the mitigation of that response using gold standard compounds, Dexamethasone and TAK-242. The reproducibility of our model enables direct comparison of the efficacy of novel treatments within and across chemical series. The model emulates many of the pro-inflammatory biomarkers present in humans (IL-6 data only shown), both in the circulatory system and tissues. The flexibility of readout from a single intraperitoneal dose provides a robust platform to investigate therapeutic interventions targeting excessive inflammation in both the periphery and a variety of tissues.